stockrowArcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024.
- Revenue
- +45.1%
- EPS
- +12.0%
- Free cash flow
- +1,171.9%
- Total debt
- +0.83%
Quarter to September 2026, against a year earlier
Follow ARQT
Alert me
Arcutis Biotherapeutics, Inc. (ARQT) Return on assets
Arcutis Biotherapeutics, Inc.'s return on assets over the twelve months to 30 September 2026 was 6.68%, up 10.8 percentage points from fiscal 2025 (−4.13%). Over the past ten years it has ranged from −75.4% (fiscal 2018) to −4.13% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −4.13% | 36.45 |
| FY2024 | −40.6% | 25.73 |
| FY2023 | −66.3% | 6.34 |
| FY2022 | −72.7% | (14.23) |
| FY2021 | −58.4% | 8.54 |
| FY2020 | −67.0% | (13.84) |
| FY2019 | −53.1% | 22.24 |
| FY2018 | −75.4% | (57.23) |
| FY2017 | −18.1% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ARQT Arcutis Biotherapeutics, Inc. | 6.68% |
| LEGN Legend Biotech Corporation Sponsored ADR compare | −5.32% |
| ABCL AbCellera Biologics Inc. compare | −12.2% |
| TNGX Tango Therapeutics, Inc. compare | −18.9% |
| DNTH Dianthus Therapeutics, Inc. compare | −21.8% |
| IOVA Iovance Biotherapeutics, Inc. compare | −23.3% |
| RLAY Relay Therapeutics, Inc. compare | −33.7% |
| EWTX Edgewise Therapeutics, Inc. compare | −36.1% |
| DFTX Definium Therapeutics, Inc. compare | −51.4% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on ARQT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- Beneish M-score
- The full statement